Abstract
Studies about the pathogenesis of mood disorders have consistently shown
that multiple factors, including genetic and environmental, play a crucial role
on their development and neurobiology. Multiple pathological theories have
been proposed, of which several ultimately affects or is a consequence of
dysfunction in brain neuroplasticity and homeostatic mechanisms. However,
current clinical available pharmacological intervention, which is predominantly
monoamine-based, suffers from partial and lacking response even after weeks of
continuous treatment. These issues raise the need for better understanding of
aetiologies and brain abnormalities in depression, as well as developing novel
treatment strategies. Nitric oxide (NO) is a gaseous unconventional neurotransmitter, which regulates and governs several important physiological functions in the central nervous system, including processes, which can be associated with the development of mood disorders. This review will present general aspects of the NO system in depression, highlighting potential targets which may be utilized and further explored as novel therapeutic targets in the future pharmacotherapy of depression. In particular, the review will link the importance of neuroplasticity mechanisms governed by NO to a possible molecular basis for the antidepressant effects.
that multiple factors, including genetic and environmental, play a crucial role
on their development and neurobiology. Multiple pathological theories have
been proposed, of which several ultimately affects or is a consequence of
dysfunction in brain neuroplasticity and homeostatic mechanisms. However,
current clinical available pharmacological intervention, which is predominantly
monoamine-based, suffers from partial and lacking response even after weeks of
continuous treatment. These issues raise the need for better understanding of
aetiologies and brain abnormalities in depression, as well as developing novel
treatment strategies. Nitric oxide (NO) is a gaseous unconventional neurotransmitter, which regulates and governs several important physiological functions in the central nervous system, including processes, which can be associated with the development of mood disorders. This review will present general aspects of the NO system in depression, highlighting potential targets which may be utilized and further explored as novel therapeutic targets in the future pharmacotherapy of depression. In particular, the review will link the importance of neuroplasticity mechanisms governed by NO to a possible molecular basis for the antidepressant effects.
| Original language | English |
|---|---|
| Journal | Cell and Tissue Research |
| Volume | 377 |
| Issue | 1 |
| Pages (from-to) | 45-58 |
| Number of pages | 14 |
| ISSN | 0302-766X |
| DOIs | |
| Publication status | Published - Jul 2019 |
Keywords
- Antidepressants
- BDNF
- Depression
- Neuroplasticity
- Nitric oxide
- METHYLENE-BLUE
- NEUROTROPHIC FACTOR
- NEURONAL NOS INHIBITOR
- FORCED SWIMMING TEST
- SOLUBLE GUANYLATE-CYCLASE
- SEROTONIN REUPTAKE INHIBITORS
- SENSITIVE LINE RATS
- SMALL-MOLECULE INHIBITORS
- MAJOR DEPRESSIVE DISORDER
- PITUITARY-ADRENAL AXIS
- Neurotransmitter Agents/pharmacology
- Humans
- Nitric Oxide/metabolism
- Mood Disorders/drug therapy
- Brain/drug effects
- Signal Transduction
- Rats
- Antidepressive Agents/pharmacology
- Brain-Derived Neurotrophic Factor/metabolism
- Animals
- Neuronal Plasticity
- Mice